Pemigatinib
Phase 2RecruitingInterest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Pancreatic Carcinoma
Conditions
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Trial Timeline
Aug 26, 2025 → Dec 31, 2028
NCT ID
NCT06906562About Pemigatinib
Pemigatinib is a phase 2 stage product being developed by Incyte for Advanced Pancreatic Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06906562. Target conditions include Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Pancreatic Carcinoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03906357 | Pre-clinical | Completed |
| NCT07434843 | Phase 2 | Recruiting |
| NCT06300528 | Phase 2 | Recruiting |
| NCT06906562 | Phase 2 | Recruiting |
| NCT06653777 | Phase 2 | Recruiting |
| NCT05565794 | Phase 2 | Terminated |
| NCT05267106 | Phase 2 | Terminated |
| NCT05253807 | Phase 2 | Completed |
| NCT03914794 | Phase 2 | Completed |
| NCT04294277 | Phase 2 | Terminated |
| NCT04003623 | Phase 2 | Terminated |
| NCT03822117 | Phase 2 | Terminated |
| NCT03235570 | Phase 1 | Completed |
| NCT03011372 | Phase 2 | Completed |
| NCT02924376 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced Pancreatic Carcinoma